Cellectar Biosc (CLRB) Stock Price, Quote & News

Company Profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort,...

Industry: Biotechnology

Sector: Healthcare

Phone: 608 441 8120

Website: www.cellectar.com

Address:

100 Campus Drive, Florham Park, United States

EvenBetter99 Feb. 3 at 4:12 PM

$CLRB very much undervalued 🚀🚀🚀🚀

0 · Reply

bananastand1203 Feb. 2 at 9:49 PM

$CLRB wondering if I should buy more. I know radiopharma is hot and I believe this is one of the best platforms. Caruso mentioned at JPM they were going to start the confirmatory study with their partner in Q1, which means that an announcement must be near. But also don’t trust Caruso and already under water in this investment

1 · Reply

EvenBetter99 Feb. 2 at 4:00 PM

$CLRB you dont get my shares cheap - long and strong 🚀🚀🚀🚀

0 · Reply

RadioIsotope25 Feb. 1 at 12:35 AM

RAD202 utilizes a nanobody to deliver Lu-177 New Nanoparticles Hold Promise for Radiopharmaceuticals Efficiency $RADX $ATNM $CLRB http://www.iaea.org/newscenter/news/new-nanoparticles-hold-promise-for-radiopharmaceuticals-efficiency

0 · Reply

Diegovj Jan. 29 at 10:16 PM

$CLRB $CATX +66% Radiopharma momentum? is real today. I wonder if some of that flows into $CLRB next.

2 · Reply

OfficialStocktwitsUser Jan. 28 at 8:07 PM

$CLRB RSI: 50.95, MACD: 0.0863 Vol: 0.32, MA20: 3.47, MA50: 3.32 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

EvenBetter99 Jan. 28 at 8:43 AM

$CLRB what if they get a strong partner for Iopofosine 131? 🚀🚀🚀🚀

1 · Reply

RunningTime2025 Jan. 26 at 8:26 PM

$CLRB heading back $2+?

1 · Reply

EvenBetter99 Jan. 25 at 6:31 PM

$CLRB To date, the Company has focused on rare cancers with significant unmet need including WM, MM, sarcomas, and HGG, among others. New FDA or EMA pathway is like a gold medal for clrb PDC Technology. 🚀🚀🚀🚀

0 · Reply

Diegovj Jan. 24 at 7:04 AM

$CLRB When do you think the final CLR-131 (CLOVER-WaM) data will be released? AACR in April or EHA in June seem like the most likely spots… curious what others think.

1 · Reply

Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference

Dec 16, 2025, 8:05 AM EST - 7 weeks ago

Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies

Nov 13, 2025, 3:41 PM EST - 2 months ago

Cellectar Biosciences, Inc. (CLRB) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:20 AM EST - 2 months ago

Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 14, 2025, 8:30 AM EDT - 4 months ago

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

Sep 11, 2025, 8:05 AM EDT - 5 months ago

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225

Sep 9, 2025, 8:05 AM EDT - 5 months ago

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Sep 5, 2025, 8:45 AM EDT - 5 months ago

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

Sep 3, 2025, 8:05 AM EDT - 5 months ago

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research

Aug 27, 2025, 8:05 AM EDT - 5 months ago

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

Aug 14, 2025, 12:25 PM EDT - 6 months ago

Cellectar Biosciences, Inc. (CLRB) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:19 AM EDT - 6 months ago

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 7, 2025, 8:05 AM EDT - 6 months ago

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

Jul 2, 2025, 4:15 PM EDT - 7 months ago

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

Jul 1, 2025, 9:25 AM EDT - 7 months ago

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

Jun 26, 2025, 8:05 AM EDT - 7 months ago

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Jun 24, 2025, 8:30 AM EDT - 8 months ago

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

Jun 18, 2025, 4:30 PM EDT - 8 months ago

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

$Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma$

Jun 11, 2025, 8:05 AM EDT - 8 months ago

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

Jun 5, 2025, 9:00 AM EDT - 8 months ago

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

Jun 4, 2025, 8:05 AM EDT - 8 months ago

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

May 13, 2025, 2:17 PM EDT - 9 months ago

Cellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:05 AM EDT - 9 months ago

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 7, 2025, 8:05 AM EDT - 9 months ago

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

Apr 30, 2025, 8:05 AM EDT - 9 months ago

Cellectar Announces Plan to Explore Strategic Alternatives

Mar 13, 2025, 12:41 PM EDT - 11 months ago

Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 7:05 AM EDT - 11 months ago

Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

Mar 5, 2025, 8:05 AM EST - 11 months ago

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

Feb 5, 2025, 8:05 AM EST - 1 year ago

Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 12, 2025, 6:00 PM EST - 1 year ago

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

Dec 11, 2024, 11:25 AM EST - 1 year ago

Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options

Dec 10, 2024, 5:00 PM EST - 1 year ago

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

Nov 21, 2024, 8:00 AM EST - 1 year ago

NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)

Nov 18, 2024, 10:59 AM EST - 1 year ago

Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript

Nov 18, 2024, 7:05 AM EST - 1 year ago

Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

Nov 14, 2024, 8:05 AM EST - 1 year ago

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225

Nov 12, 2024, 8:05 AM EST - 1 year ago

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

Nov 11, 2024, 4:05 PM EST - 1 year ago

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

Nov 7, 2024, 6:40 AM EST - 1 year ago

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

Nov 1, 2024, 5:00 PM EDT - 1 year ago

Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

Aug 26, 2024, 6:40 AM EDT - 1 year ago

Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia

Aug 23, 2024, 5:00 PM EDT - 1 year ago

Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Aug 13, 2024, 1:25 PM EDT - 1 year ago

Cellectar Biosciences, Inc. (CLRB) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update

Aug 8, 2024, 5:15 PM EDT - 1 year ago

UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

Jul 24, 2024, 3:22 PM EDT - 1 year ago

Cellectar Biosciences, Inc. (CLRB) KOL and Analyst Day Call Transcript

Jul 23, 2024, 3:09 PM EDT - 1 year ago

Cellectar: WM Treatment Data Leads To A Few Regulatory Milestones

Jul 23, 2024, 10:49 AM EDT - 1 year ago

Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study

Jul 23, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months

Jul 22, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million

EvenBetter99 Feb. 3 at 4:12 PM

$CLRB very much undervalued 🚀🚀🚀🚀

0 · Reply

bananastand1203 Feb. 2 at 9:49 PM

1 · Reply

EvenBetter99 Feb. 2 at 4:00 PM

$CLRB you dont get my shares cheap - long and strong 🚀🚀🚀🚀

0 · Reply

RadioIsotope25 Feb. 1 at 12:35 AM

0 · Reply

Diegovj Jan. 29 at 10:16 PM

$CLRB $CATX +66% Radiopharma momentum? is real today. I wonder if some of that flows into $CLRB next.

2 · Reply

OfficialStocktwitsUser Jan. 28 at 8:07 PM

0 · Reply

EvenBetter99 Jan. 28 at 8:43 AM

$CLRB what if they get a strong partner for Iopofosine 131? 🚀🚀🚀🚀

1 · Reply

RunningTime2025 Jan. 26 at 8:26 PM

$CLRB heading back $2+?

1 · Reply

EvenBetter99 Jan. 25 at 6:31 PM

0 · Reply

Diegovj Jan. 24 at 7:04 AM

$CLRB When do you think the final CLR-131 (CLOVER-WaM) data will be released? AACR in April or EHA in June seem like the most likely spots… curious what others think.

1 · Reply

Zergg Jan. 24 at 12:30 AM

$CLRB im betting the farm on this one boys

1 · Reply

EvenBetter99 Jan. 23 at 6:13 PM

$CLRB soon several 100 M worth check website fe 🚀🚀🚀🚀

1 · Reply

JTSawyer66 Jan. 22 at 4:06 PM

$CLRB

0 · Reply

Zergg Jan. 22 at 2:33 PM

$CLRB been quiet lately

1 · Reply

Aawilliam2003 Jan. 18 at 11:18 PM

$CLRB when will Caruso give up? End coming soon

3 · Reply

EvenBetter99 Jan. 18 at 6:09 PM

$CLRB Overall WM Market Value The broader relapsed/refractory WM market in the U.S. is estimated to be valued at approximately $1 billion, with the entire U.S. WM market at around $2.1 billion. Europe similar, so 2 Billion market for WM! Approval almost certain in US and EU. 🚀🚀🚀🚀

3 · Reply

EvenBetter99 Jan. 16 at 7:08 PM

$CLRB heavily and absolutly undervalued - be smart with a strong buy 🚀🚀🚀🚀

1 · Reply

Zergg Jan. 15 at 3:02 PM

$CLRB just bought the dip

0 · Reply

Scorpole Jan. 15 at 2:48 PM

$CLRB No reason to bee too optimistisk here as long as Caruso is in charge. All talks about partnership is very likely just BS as it has been for the last year

0 · Reply

Zergg Jan. 15 at 12:38 AM

$CLRB were we mentioned tonight?

0 · Reply

revuelto Jan. 14 at 11:07 PM

$CLRB I will stop tracking this name and its tape for now…I think we are in good shape….I will check back in after either a partnership or an acquisition announcement, whichever comes first.✌️

0 · Reply

Pedelco Jan. 14 at 8:42 PM

$CLRB super bullish

0 · Reply

Market Cap	16.84M
Revenue (ttm)	0.00
Net Income (ttm)	-44.58M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,765,327
Avg Vol	14,877,256
Day's Range	N/A - N/A
Shares Out	46.08M
Stochastic %K	31%
Beta	0.52
Analysts	Sell
Price Target	$4.00